Comparing the Renal Effect of Dipeptidyl-peptidase 4 Inhibitors and Sulfonylureas

• Status: Completed
• Trial end date: 2018-02-28
• Target enrollment: 0
• Participant gender: All

Summary

Dipeptidyl peptidase 4 (DPP-4) inhibitors and sulfonylureas have been extensively used in the treatment of type 2 diabetes mellitus (T2DM). Although both medications effectively lower plasma glucose levels, differences may exist in their pharmacokinetics and effect on the kidney. In the context of diabetic kidney disease, DPP-4 inhibitors may confer renal protection through several putative mechanisms. In contrast, sulfonylureas are associated with weight gain and cardiac dysfunction, which may adversely influence kidney function.

The investigators hypothesize that DPP-4 inhibitors and sulfonylureas may have a different effect on the diabetic kidney. This study compares the effect of DPP-4 inhibitors and sulfonylureas on urinary albumin excretion in patients with newly diagnosed T2DM.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Changhua Christian Hospital
• Treatments: Dipeptidyl-Peptidase IV Inhibitors; Metformin

Criteria

Inclusion Criteria:

• Patients exceeding 20 years of age

• Patients with newly diagnosed type 2 diabetes mellitus

• Patients who have yet to receive antidiabetic medications

Exclusion Criteria:

• Patients with non-diabetic kidney disease

• Patients with congenital kidney abnormalities

• Patients with end stage renal disease.

• Patients who have received angiotensin-converting-enzyme inhibitor or angiotensin II receptor blocker